The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder

Expert Review of Neurotherapeutics

Volumn 10, Issue 10, 2010, Pages 1595-1605

  Arnsten, Amy F T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2A adrenoceptors; attention deficit hyperactivity disorder; benzedrine; cAMP signaling; clonidine; dopamine; guanfacine; norepinephrine; prefrontal cortex; stimulations

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CLONIDINE; GUANFACINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ATTENTION; ATTENTION DEFICIT DISORDER; BEHAVIOR; CLINICAL TRIAL; EMOTION; GILLES DE LA TOURETTE SYNDROME; HUMAN; NONHUMAN; PREFRONTAL CORTEX; PROTEIN FUNCTION; REVIEW; DRUG EFFECT; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR; CATECHOLAMINES; EMOTIONS; HUMANS; PREFRONTAL CORTEX; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 77958014321     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.133     Document Type: Review

References (149)

1. Barkley RA. ADHD And The Nature Of Self-Control. Guilford Press, NY, USA (1997).
2. Faraone SV, Perlis RH, Doyle AE et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1313-1323 (2005).
3. Barkley RA, Grodzinsky G, DuPaul GJ. Frontal lobe functions in attention deficit disorder with and without hyperactivity: A review and research report. J. Abnorm. Child Psych. 20, 163-188 (1992).
4. Arnsten AF, Steere JC, Hunt RD. The contribution of α2 noradrenergic mechanisms to prefrontal cortical cognitive function: Potential significance to attention deficit hyperactivity disorder. Arch. Gen. Psychiatry 53, 448-455 (1996).
5. McLean A, Dowson J, Toone B et al. Characteristic neurocognitive profile associated with adult attention-deficit/hyperactivity disorder. Psychol. Med. 34, 681-692 (2004).
6. Wilkins AJ, Shallice T, McCarthy R. Frontal lesions and sustained attention. Neuropsychologia 25, 359-365 (1987).
7. Woods DL, Knight RT. Electrophysiological evidence of increased distractability after dorsolateral prefrontal lesions. Neurology 36, 212-216 (1986).
8. Yamaguchi S, Knight RT. Gating of somatosensory input by human prefrontal cortex. Brain Res. 521, 281-288 (1990).
9. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn. Sci. 8, 170-177 (2004). Excellent review on the neural basis of inhibitory control of behavior.
10. Godefroy O, Rousseaux M. Divided and focused attention in patients with lesion of the prefrontal cortex. Brain Cogn. 30, 155-174 (1996).
11. Manes F, Sahakian BJ, Clark L et al. Decision-making processes following damage to the prefrontal cortex. Brain 125, 624-639 (2002).
12. Anderson SW, Bechara A, Damasio H et al. Impairment of social and moral behavior related to early damage in human prefrontal cortex. Nat. Neurosci. 2, 1032-1037 (1999).
13. Dickstein SG, Bannon K, Castellanos FX et al. The neural correlates of attention deficit hyperactivity disorder: An ALE meta-analysis. J. Child Psychol. Psychiatry 47, 1051-1062 (2006).
14. Rubia K, Smith AB, Brammer MJ et al. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am. J. Psychiatry 162, 1067-1075 (2005).
15. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: A review and suggested future directions. Biol. Psychiatry 57, 1273-1284 (2005).
16. Smith AB, Taylor E, Brammer M et al. Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Am. J. Psychiatry 163, 1044-1051 (2006).
17. Castellanos FX, Lee PP, Sharp W et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA 288, 1740-1748 (2002).
18. Makris N, Biederman J, Valera EM et al. Cortical thinning of the attention and executive function networks in adults with attention-deficit/ hyperactivity disorder. Cereb Cortex. 17, 1364-1375 (2007).
19. Seidman LJ, Valera EM, Makris N et al. Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. Biol. Psychiatry 60, 1071-1080 (2006).
20. Valera EM, Faraone SV, Murray KE et al. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol. Psychiatry 15, 1361-1369 (2007).
21. Brown AB, Biederman J, Valera EM et al. Effect of dopamine transporter gene (SLC6A3) variation on dorsal anterior cingulate function in attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 365-375 (2010).
22. Durston S, Fossella JA, Casey BJ et al. Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls. Mol. Psychiatry 10, 678-685 (2005).
23. Casey BJ, Epstein JN, Buhle J et al. Frontostriatal connectivity and its role in cognitive control in parent-child dyads with ADHD. Am. J. Psychiatry 164, 1729-1736 (2007).
24. Castellanos FX, Margulies DS, Kelly C et al. Cingulate-precuneus interactions: A new locus of dysfunction in adult attention-deficit/ hyperactivity disorder. Biol. Psychiatry 63, 332-337 (2008).
25. Makris N, Buka SL, Biederman J et al. Attention and executive systems abnormalities in adults with childhood ADHD: A DT-MRI study of connections. Cereb. Cortex 18, 1210 (2008).
26. Shaw P, Eckstrand K, Sharp W et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc. Natl Acad. Sci. USA 104, 19649-19654 (2007).
27. Knight RT, Grabowecky MF, Scabini D. Role of human prefrontal cortex in attention control. Adv. Neurol. 66, 21-34 (1995).
28. Robbins TW. Dissociating executive functions of the prefrontal cortex. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351, 1463-1471 (1996).
29. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: Motor and cognitive circuits. Brain Res. Brain Res. Rev. 31, 236-250 (2000).
30. Damasio AR. The somatic marker hypothesis and the possible functions of the prefrontal cortex. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351, 1413-1420 (1996).
31. Dias R, Robbins TW, Roberts AC. Dissociable forms of inhibitory control within prefrontal cortex with an analog of the Wisconsin Card Sort Test: Restriction to novel situations and independence from 'on-line' processing. J. Neurosci. 17, 9285-9297 (1997).
32. Rolls ET. The orbitofrontal cortex and reward. Cereb. Cortex 10, 284-294 (2000).
33. van Veen V, Carter CS. The anterior cingulate as a conflict monitor: FMRI and ERP studies. Physiol. Behav. 77, 477-482 (2002).
34. Fuster JM. Unit activity in prefrontal cortex during delayed response performance: Neuronal correlates of transient memory. J. Neurophysiol. 36, 61-78 (1973). One of the first studies to discover persistent firing of prefrontal cortex (PFC) neurons during the delay period of a working memory task.
35. Funahashi S, Bruce CJ, Goldman-Rakic PS. Mnemonic coding of visual space in the monkey's dorsolateral prefrontal cortex. J. Neurophysiol. 61, 331-349 (1989).
36. Miller EK, Erickson CA, Desimone R et al. Neural mechanisms of visual working memory in prefrontal cortex of the macaque. J. Neurosci. 16, 5154-5167 (1996). (Pubitemid 26269674)
37. Funahashi S, Chafee MV, Goldman-Rakic PS. Prefrontal neuronal activity in rhesus monkeys performing a delayed anti-saccade task. Nature 365, 753-756 (1993).
38. Boucher L, Palmeri TJ, Logan GD et al. Inhibitory control in mind and brain: An interactive race model of countermanding saccades. Psychol. Rev. 114, 376-397 (2007).
39. Buschman TJ, Miller EK. Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science 315, 1860-1862 (2007).
40. Barraclough DJ, Conroy ML, Lee D. Prefrontal cortex and decision making in a mixed-strategy game. Nat. Neurosci. 7, 404-410 (2004).
41. Wallis JD, Anderson KC, Miller EK. Single neurons in prefrontal cortex encode abstract rules. Nature 411, 953-956 (2001).
42. Rolls ET, Critchley HD, Mason R et al. Orbitofrontal cortex neurons: Role in olfactory and visual association learning. J. Neurophysiol. 75, 1970-1981 (1996).
43. Goldman-Rakic PS. Cellular basis of working memory. Neuron 14, 477-485 (1995). Excellent review of the neural basis of working memory, and the PFC microcircuits subserving our 'mental sketch pad'.
44. Arnsten AF, Paspalas CD, Gamo NJ et al. Dynamic Network Connectivity: A new form of neuroplasticity. Trends Cogn. Sci. 14(8), 365-375 (2010).
45. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: Monoaminergic modulation. Annu. Rev. Neurosci. 32, 267-287 (2009).
46. Brozoski T, Brown RM, Rosvold HE et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205, 929-931 (1979). First paper to reveal that catecholamines are critical to PFC cognitive functioning.
47. Arnsten AF, Goldman-Rakic PS. α2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230, 1273-1276 (1985).
48. Li B-M, Mei Z-T. Delayed response deficit induced by local injection of the α2 adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav. Neural Biol. 62, 134-139 (1994).
49. Wang M, Ramos B, Paspalas C et al. α2A-adrenoceptor stimulation strengthens working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 129, 397-410 (2007). Revealed the ionic basis of guanfacine's actions.
50. Arnsten AF. Through the looking glass: Differential noradrenergic modulation of prefrontal cortical function. Neural Plasticity 7, 133-146 (2000).
51. MacDonald E, Kobilka BK, Scheinin M. Gene targeting - homing in on a-2-adrenoceptor subtype function. Trends Pharmacol. Sci. 18, 211-219 (1997).
52. Winzer-Serhan UH, Leslie FM. α-2B adrenoceptor mRNA expression during rat brain development. Brain Res. Dev. Brain Res. 100, 90-100 (1997).
53. Buzsaki G, Kennedy B, Solt VB et al. Noradrenergic control of thalamic oscillation: The role of α2 receptors. Eur. J. Neurosci. 3, 222-229 (1991).
54. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: Modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 42, 33-84 (2003).
55. Nelson LE, Lu J, Guo T et al. The α2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 98, 428-436 (2003).
56. U'Prichard DC, Bechtel WD, Rouot BM et al. Multiple apparent α-noradrenergic receptor binding sites in rat brain: Effect of 6-hydroxydopamine. Mol. Pharmacol. 16, 47-60 (1979). Discovered that the majority of α2 receptors in brain are postsynaptic to norepinephrine (NE) neurons.
57. Arnsten AF, Cai JX, Goldman-Rakic PS. The α2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. J. Neurosci. 8, 4287-4298 (1988).
58. Franowicz JS, Kessler L, Dailey-Borja CM et al. Mutation of the α2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22, 8771-8777 (2002).
59. Cai JX, Ma Y, Xu L et al. Reserpine impairs spatial working memory performance in monkeys: Reversal by the α2 adrenergic agonist clonidine. Brain Res. 614, 191-196 (1993). Demonstrated that clonidine's beneficial effects on working memory were through actions at postsynaptic, not presynaptic, receptors.
60. Aoki C, Venkatesan C, Go C-G et al. Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons. Cereb. Cortex 8, 269-277 (1998).
61. Aston-Jones G, Rajkowski J, Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog. Brain Res. 126, 165-182 (2000).
62. Vijayraghavan S, Wang M, Birnbaum SG et al. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 10, 376-384 (2007).
63. Schultz W. The phasic reward signal of primate dopamine neurons. Adv. Pharmacol. 42, 686-690 (1998).
64. Goldstein LE, Rasmusson AM, Bunney SB et al. Role of the amygdala in the coordination of behavioral, neuroendocrine and prefrontal cortical monoamine responses to psychological stress in the rat. J. Neurosci. 16, 4787-4798 (1996).
65. Brischoux F, Chakraborty S, Brierley DI et al. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc. Natl Acad. Sci. USA 106(12), 4894-4899 (2009).
66. Birnbaum SB, Yuan P, Bloom A et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 306, 882-884 (2004).
67. Arnsten AF. Stress signaling pathways that impair prefrontal cortex structure and function. Nat. Rev. Neurosci. 32, 267-287 (2009).
68. Ferry B, Roozendaal B, McGaugh JL. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between β- and α-1-adrenoceptors. J. Neurosci. 19, 5119-5123 (1999).
69. Nader K, LeDoux JE. Inhibition of the mesoamygdala dopaminergic pathway impairs the retrieval of conditioned fear associations. Behav. Neurosci. 113, 891-901 (1999).
70. 2+ channels regulates synaptic excitability in the medial prefrontal cortex. J. Physiol. 588, 1281-1292 (2010).
71. Hagenston AM, Fitzpatrick JS, Yeckel MF. MGluR-mediated calcium waves that invade the soma regulate firing in layer V medial prefrontal cortical pyramidal neurons. Cereb. Cortex 18, 407-423 (2008).
72. Ramos B, Stark D, Verduzco L et al. α-2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn. Mem. 13, 770-776 (2006).
73. Rama P, Linnankoski I, Tanila H et al. Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol. Biochem. Behav. 54, 1-7 (1996).
74. O'Neill J, Fitten LJ, Siembieda DW et al. Effects of guanfacine on three forms of distraction in the aging macaque. Life Sci. 67, 877-885 (2000).
75. Jakala P, Riekkinen M, Sirvio J et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 20, 460-470 (1999).
76. Avery RA, Franowicz JS, Studholme C et al. The α-2A-adenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 23, 240-249 (2000).
77. Swartz BE, Kovalik E, Thomas K et al. The effects of an α2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy. Neuropsychopharmacology 23, 263-275 (2000).
78. Clerkin SM, Schulz KP, Halperin JM et al. Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. Biol. Psychiatry 66, 307-312 (2009).
79. Mao Z-M, Arnsten AFT, Li BM. Local infusion of a-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol. Psychiatry 46, 1259-1265 (1999).
80. Steere JC, Arnsten AF. The α-2A noradrenergic agonist, guanfacine, improves visual object discrimination reversal performance in rhesus monkeys. Behav. Neurosci. 111, 1-9 (1997).
81. Li BM, Mao ZM, Wang M et al. α2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology 21, 601-610 (1999).
82. Ma CL, Qi XL, Peng JY et al. Selective deficit in no-go performance induced by blockade of prefrontal cortical α2-adrenoceptors in monkeys. Neuroreport 14, 1013-1016 (2003).
83. Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical a-2-adrenoceptors in monkeys. Biol. Psychiatry 57, 192-195 (2005).
84. Kopecková M, Paclt I, Goetz P. Polymorphisms of dopamine-b-hydroxylase in ADHD children. Folia Biol. (Praha) 52, 194-210 (2006).
85. Comings DE, Gade-Andavolu R, Gonzalez N et al. Additive effect of three noradrenergic genes (ADRA2A, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin. Genet. 55, 160-172 (1999).
86. Daly G, Hawi Z, Fitzgerald M et al. Mapping susceptibility loci in attention deficit hyperactivity disorder: Preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry 4, 192-196. (1999).
87. Roman T, Schmitz M, Polanczyk GV et al. Further evidence for the association between attention-deficit/hyperactivity disorder and the dopamine-b-hydroxylase gene. Am. J. Med. Genet. 114, 154-158. (2002).
88. Greene CM, Bellgrove MA, Gill M et al. Noradrenergic genotype predicts lapses in sustained attention. Neuropsychologia 47, 591-594 (2009).
89. Hess C, Reif A, Strobel A et al. A functional dopamine-b-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J. Neural Transm. 116, 121-130 (2009).
90. Kieling C, Genro JP, Hutz MH et al. The -1021 C/T DBH polymorphism is associated with neuropsychological performance among children and adolescents with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 485-490 (2008).
91. Roman T, Schmitz M, Polanczyk GV et al. Is the α-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am. J. Med. Genet. B Neuropsychiatr. Genet. 120, 116-120 (2003).
92. Park L, Nigg JT, Waldman ID et al. Association and linkage of α-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol. Psychiatry 10, 572-580 (2005).
93. Deupree JD, Smith SD, Kratochvil CJ et al. Possible involvement of α-2A adrenergic receptors in attention deficit hyperactivity disorder: Radioligand binding and polymorphism studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 877-884 (2006).
94. Waldman ID, Nigg JT, Gizer IR et al. The adrenergic receptor α-2A gene (ADRA2A) and neuropsychological executive functions as putative endophenotypes for childhood ADHD. Cogn. Affect. Behav. Neurosci. 6, 18-30 (2006).
95. Hunt RD, Mindera RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: Reports of a double-blind placebo-crossover therapeutic trial. J. Am. Acad. Child Psychiatry 24, 617-629 (1985).
96. Cohen DJ, Young JG, Nathanson JA et al. Clonidine in Tourette's syndrome. Lancet 2, 551-553 (1979).
97. Cedarbaum JM, Aghajanian GK. Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization. Eur. J. Pharmacol. 44, 375-385 (1977).
98. Aghajanian GK. Central noradrenergic neurons: A locus for the functional interplay between α2 adrenoceptors and opiate receptors. J. Clin. Psychiatry 43, 20-24 (1982).
99. Cohen DJ. Sterling Lecture, February 27, 2001 "Into life: Autism, Tourette's syndrome and the community of clinical research". Isr. J. Psychiatry 38, 226-234 (2001).
100. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. J. Child Adolesc. Psychiatry 1, 87-102 (1990).
101. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27, 699-711 (2002).
102. Berridge CW, Devilbiss DM, Andrzejewski ME et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry 60, 1111-1120 (2006). Demonstrates that methylphenidate has prominent NE actions in PFC, in addition to its well-known dopamine actions.
103. Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: Relationships to baseline memory capacity. J. Child Psychol. Psychiatry 45, 293-305 (2004).
104. Mehta MA, Owen AM, Sahakian BJ et al. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci. 20, RC65 (2000). Demonstrates that methylphenidate improves performance and enhances PFC efficiency in normal subjects.
105. Chamberlain SR, Del Campo N, Dowson J et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol. Psychiatry 62, 977-984 (2007).
106. Devilbiss DM, Berridge CW. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness. Biol. Psychiatry 64, 626-635 (2008).
107. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav. Brain Funct. 1, 2 (2005).
108. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine improve prefrontal cortical function via noradrenergic α2 and dopaminergic D1 receptor stimulation. J. Am. Acad. Child Adolesc. Psychiatry (2010) (In press).
109. Volkow ND, Fowler JS, Wang GJ et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: Results from imaging studies. Eur. Neuropsychopharmacol. 12, 557-566 (2002).
110. Zhu J, Reith ME. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol. Disord. Drug Targets 7, 393-409 (2008).
111. Polanczyk G, Zeni C, Genro JP et al. Association of the adrenergic α2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 64, 218-224 (2007).
112. Uhlen S, Wikberg JE. Delineation of rat kidney a 2A and a 2B-adrenoceptors with [3H]RX821002 radioligand binding: Computer modeling reveals that guanfacine is an α-2A-selective compound. Eur. J. Pharmacol. 202, 235-243 (1991).
113. Uhlén S, Muceniece R, Rangel N et al. Comparison of the binding activities of some drugs on α 2A, α 2B and α 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Pharmacol. Toxicol. 76, 353-364 (1995).
114. Jasper JR, Lesnick JD, Chang LK et al. Ligand efficacy and potency at recombinant α2 adrenergic receptors: Agonist-mediated [35S]GTPγS binding. Biochem. Pharmacol. 55, 1035-1043 (1998).
115. Sorkin EM, Heel RC. Guanfacine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31, 301-336 (1986).
116. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 34, 50-54 (1995).
117. Scahill L, Chappell PB, Kim YS et al. Guanfacine in the treatment of children with tic disorders and ADHD: A placebo-controlled study. Am. J. Psychiatry 158, 1067-1074 (2001). First placebo-controlled trial of guanfacine in patients with attention-deficit/hyperactivity disorder symptoms.
118. Spencer TJ, Greenbaum M, Ginsberg LD et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 19, 501-510 (2009).
119. Biederman J, Melmed RD, Patel A et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121, e73-e84 (2008).
120. Sallee FR, McGough JJ, Wigal T et al. Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 48, 155-165 (2009).
121. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 23(Suppl. 1), 21-31 (2009).
122. Birnbaum SG, Arnsten AF. The α-2A noradrenergic agonist, guanfacine, reverses the working memory deficits induced by pharmacological stress (FG7142). Soc. Neurosci. Abstracts 22, 1126 (1996).
123. Rubia K, Smith AB, Halari R et al. Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention. Am. J. Psychiatry 166, 83-94 (2009).
124. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 105, 38-48 (2010).
125. Sinha R. The role of stress in addiction relapse. Curr. Psychiatry Rep. 9, 388-395 (2007).
126. Scahill L, Aman MG, McDougle CJ et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 16, 589-598 (2006).
127. McCracken JT, Aman MG, McDougle CJ et al. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J. Child Adolesc. Psychopharmacol. 20, 1-5 (2010).
128. Malhotra PA, Parton AD, Greenwood R et al. Noradrenergic modulation of space exploration in visual neglect. Ann. Neurol. 59, 186-190 (2006).
129. Singh-Curry V, Malhotra P, Farmer SF et al. Attention deficits following ADEM ameliorated by guanfacine. J. Neurol. Neurosurg. Psychiatry DOI: 10.1136/jnnp.2009.195792 (2010) (Epub ahead of print).
130. Moore TL, Killiany RJ, Herndon JG et al. Executive system dysfunction occurs as early as middle-age in the rhesus monkey. Neurobiol. Aging 27, 1484-1493 (2006).
131. West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol. Bull. 120, 272-292 (1996).
132. Daviss WB, Patel NC, Robb AS et al. Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J. Am. Acad. Child Adolesc. Psychiatry 47, 189-198 (2008).
133. Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch. Pediatr. Adolesc. Med. 156, 392-396 (2002).
134. Sallee FR, Lyne A, Wigal T et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 19, 215-226 (2009).
135. van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc. Drugs Ther. 8, 787-799 (1994).
136. Bradley C. The behavior of children receiving benzedrine. Am. J. Psychiatry 94, 577-585 (1937).
137. Arnsten AF, Ramos B, Birnbaum SB et al. Protein kinase A as a therapeutic target for memory disorders: Rationale and challenges. Trends Mol. Med. 11, 121-128 (2005).
138. Giedd JN, Lalonde FM, Celano MJ et al. Anatomical brain magnetic resonance imaging of typically developing children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 48, 465-470 (2009).
139. Millar JK, Pickard BS, Mackie S et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310, 1187-1191 (2005).
140. Kirkpatrick B, Xu L, Cascella N et al. DISC1 immunoreactivity at the light and ultrastructural level in the human neocortex. J. Comp. Neurol. 497, 436-450 (2006).
141. Murdoch H, Mackie S, Collins DM et al. Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J. Neurosci. 27, 9513-9524 (2007).
142. Lambe EK, Olausson P, Horst NK et al. Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: Correlation with improved attention in rat. J. Neurosci. 25, 5225-5229 (2005).
143. Pons S, Fattore L, Cossu G et al. Crucial role of a4 and a6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J. Neurosci. 28, 12318-12327 (2008).
144. Clarke HF, Walker SC, Dalley JW et al. Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb. Cortex 17, 18-27 (2007).
145. McClure MM, Barch DM, Romero MJ et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol. Psychiatry 61, 1157-1160 (2007).
146. Swartz BE, McDonald CR, Patel A et al. The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls. Clin. Neuropharmacol. 31, 251-260 (2008).
147. Arnsten AF, Contant TA. α2 adrenergic agonists decrease distractability in aged monkeys performing a delayed response task. Psychopharmacology 108, 159-169 (1992).
148. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention deficit-hyperactivity disorder. J. Clin. Psychopharm. 21, 223-228 (2001).
149. Wang M, Tang ZX, Li BM. Enhanced visuomotor associative learning following stimulation of α 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res. 1024, 176-182 (2004).